137 related articles for article (PubMed ID: 1777014)
1. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balazs C; Farid NR
J Autoimmun; 1991 Aug; 4(4):681-8. PubMed ID: 1777014
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balázs C; Farid NR
Acta Med Hung; 1991; 48(1-2):3-11. PubMed ID: 1813855
[TBL] [Abstract][Full Text] [Related]
3. Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balázs CS
Biomed Pharmacother; 1991; 45(7):311-4. PubMed ID: 1760523
[TBL] [Abstract][Full Text] [Related]
4. Methimazole has no dose-related effect on the serum concentrations of soluble class I major histocompatibility complex antigens, soluble interleukin-2 receptor, and beta 2-microglobulin in patients with Graves' disease.
Escobar-Morreale HF; Serrano-Gotarredona J; Villar LM; García-Robles R; González-Porqué P; Sancho JM; Varela C
Thyroid; 1996 Feb; 6(1):29-36. PubMed ID: 8777381
[TBL] [Abstract][Full Text] [Related]
5. [Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy].
Yang H; Wu Z; Huang X; Xie C; Yang P
Yan Ke Xue Bao; 1999 Jun; 15(2):78-80. PubMed ID: 12579704
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function and thyroid autoimmunity independently modulate serum concentration of soluble interleukin 2 (IL-2) receptor (sIL-2R) in thyroid diseases.
Mariotti S; Caturegli P; Barbesino G; Marinò M; Del Prete GF; Chiovato L; Tonacchera M; De Carli M; Pinchera A
Clin Endocrinol (Oxf); 1992 Nov; 37(5):415-22. PubMed ID: 1486691
[TBL] [Abstract][Full Text] [Related]
7. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
[TBL] [Abstract][Full Text] [Related]
8. Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Van der Gaag R; Mourits MP; Koornneef L
Clin Exp Immunol; 1992 Jun; 88(3):405-9. PubMed ID: 1606722
[TBL] [Abstract][Full Text] [Related]
9. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism.
Mariotti S; Caturegli P; Barbesino G; Del Prete GF; Chiovato L; Pinchera A
J Endocrinol Invest; 1991 Oct; 14(9):777-81. PubMed ID: 1761814
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in soluble interleukin-2 receptor levels during treatment of Graves' disease. Correlation with disease activity.
Weryha G; Gobert B; Leclère J; Béné MC; Faure G; Hartemann P
Horm Res; 1991; 35(1):8-12. PubMed ID: 1916654
[TBL] [Abstract][Full Text] [Related]
11. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
[TBL] [Abstract][Full Text] [Related]
12. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
13. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
15. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease.
Tötterman TH; Karlsson FA; Bengtsson M; Mendel-Hartvig I
N Engl J Med; 1987 Jan; 316(1):15-22. PubMed ID: 2946953
[TBL] [Abstract][Full Text] [Related]
16. Graves' Disease with Thymic Hyperplasia: The Response of the Thyroid Function, Thyrotropin Receptor Autoantibody, and Thymic Size to Thiamazole Treatment.
Tsukada D; Iizuka K; Takao K; Liu Y; Kubota S; Okamoto-Kubota S; Sakurai T; Imaizumi T; Sakai M; Kato T; Mizuno M; Hirota T; Suwa T; Horikawa Y; Yamamoto M; Kubota S; Yabe D
Intern Med; 2022 Sep; 61(18):2753-2757. PubMed ID: 35228417
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent effect of cyclosporin-A on the TSH-receptor antibody synthesis in patients with Graves' disease.
Balázs C; Kiss E; Farid NR
Acta Med Hung; 1988; 45(1):43-52. PubMed ID: 3412862
[TBL] [Abstract][Full Text] [Related]
18. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.
Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA
Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576
[TBL] [Abstract][Full Text] [Related]
19. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
20. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
